应用吡柔比星加α-干扰素行膀胱灌注防治膀胱癌术后复发

The observation on clinical effect of pirarubicin and recombinant human interferon a2b intravesical instillation chemotherapy on bladder cancer

目的探讨应用吡柔比星加α-干扰素行膀胱灌注防治膀胱癌术后复发的临床疗效和安全性。方法将53例患者随机分成两组,观察组27例和对照组26例,TUR-BT术后,观察组膀胱灌注化疗应用吡柔比星和α-干扰素,对照组采用吡柔比星,观察两组患者的化疗不良反应发生率,随访2年比较复发率和生存率等。结果两组患者不良反应发生率差异无统计学意义(P>0.05),但是随访2年,观察组患者复发率和生存率分别为14.81%(4/27)、100%(27/27),明显优于对照组的26.92%(7/26)、88.46%(23/26),差异存在统计学意义(P<0.05)。结论应用吡柔比星加α-干扰素行膀胱灌注化疗安全有效,具有复发率低、生存率高等优点,值得临床推广应用。

Objective To observe the clinical effect and safety of pirarubicin and recombinant human interferon a2b intravesical instillation chemotherapy on bladder cancer.Methods 53 patients with bladder cancer were randomly divided into the intervention group（27cases） and control group（26 cases）;The patients were firstTUR-BT,and then the intervention group were treated with pirarubicin and recombinant human interferon a2b,the control group were treated with pirarubicin;The incidence of adverse reactions,recurrence rate and survival rates were observed and compared,after following-up for2 years.Results Their incidence of adverse reactions were no difference（P0.05）,after following-up for 2 years,the recurrence rate and survival rates in the intervention group were respectively 14.81%（4/27）、100%（27/27）,they were better 26,92%（7/26）、88.46%（23/26） in the control group,there were significant differences（P0.05）.Conclusion The linstillation of pirarubicin and recombinant human interferon a2b chemotherapy on bladder cancer after TUR-BT is more effective and safely,has low recurrence rate and high survival rate,and hence is worthy of being recommended in clinical practice.